Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-eye follow-on gene therapy study in previously treated X-linked retinitis pigmentosa
ISRCTN57691385Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with adverse events. Started Apr 2025; status: active, not recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on ISRCTN57691385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57691385.